

David M Livermore

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7112129/publications.pdf>

Version: 2024-02-01

121
papers

17,728
citations

32410

55
h-index

21239

119
g-index

121
all docs

121
docs citations

121
times ranked

16795
citing authors

#	ARTICLE	IF	CITATIONS
1	Understanding decisions about antibiotic prescribing in ICU: an application of the Necessity Concerns Framework. <i>BMJ Quality and Safety</i> , 2022, 31, 199-210.	1.8	33
2	AmpC hyperproduction in a <i>Cedecea davisae</i> implant-associated bone infection during treatment: a case report and therapeutic implications. <i>BMC Infectious Diseases</i> , 2022, 22, 33.	1.3	3
3	Multicentre evaluation of two multiplex PCR platforms for the rapid microbiological investigation of nosocomial pneumonia in UK ICUs: the INHALE WP1 study. <i>Thorax</i> , 2022, 77, 1220-1228.	2.7	39
4	Impact of changed co-amoxiclav susceptibility testing formats on apparent resistance rates for bloodstream <i>Escherichia coli</i> in a long-term surveillance. <i>Journal of Antimicrobial Chemotherapy</i> , 2022, , .	1.3	0
5	Fosfomycin Trometamol for the Prevention of Infectious Complications After Prostate Biopsy: A Consensus Statement by an International Multidisciplinary Group. <i>European Urology Focus</i> , 2022, 8, 1483-1492.	1.6	5
6	SUSceptibility and Resistance to Fosfomycin and other antimicrobial agents among pathogens causing lower urinary tract infections: findings of the SURF study. <i>International Journal of Antimicrobial Agents</i> , 2022, 59, 106574.	1.1	16
7	COVID-19 vaccination and HIV-1 acquisition. <i>Lancet, The</i> , 2022, 399, e34-e35.	6.3	3
8	Inoculum effects of cefepime/zidebactam (WCK 5222) and ertapenem/zidebactam (WCK 6777) for Enterobacterales in relation to β -lactamase type and enhancer effect, as tested by BSAC agar dilution. <i>Journal of Antimicrobial Chemotherapy</i> , 2022, , .	1.3	3
9	Activity of β -lactam/taniborbactam (VNRX-5133) combinations against carbapenem-resistant Gram-negative bacteria. <i>Journal of Antimicrobial Chemotherapy</i> , 2021, 76, 160-170.	1.3	29
10	Whatâ€™s left in the cupboard? Older antimicrobials for treating gonorrhoea. <i>Journal of Antimicrobial Chemotherapy</i> , 2021, 76, 1215-1220.	1.3	8
11	Activity of cefepime/zidebactam (WCK 5222) against â€˜problemâ€™ antibiotic-resistant Gram-negative bacteria sent to a national reference laboratory. <i>Journal of Antimicrobial Chemotherapy</i> , 2021, 76, 1511-1522.	1.3	17
12	Are resistance rates among bloodstream isolates a good proxy for other infections? Analysis from the BSAC Resistance Surveillance Programme. <i>Journal of Antimicrobial Chemotherapy</i> , 2021, 76, 1822-1831.	1.3	1
13	Cefepime/tazobactam compared with other tazobactam combinations against problem Gram-negative bacteria. <i>International Journal of Antimicrobial Agents</i> , 2021, 57, 106318.	1.1	9
14	Antibiotic resistance during and beyond COVID-19. <i>JAC-Antimicrobial Resistance</i> , 2021, 3, i5-i16.	0.9	23
15	Co-trimoxazole to reduce mortality, transplant, or unplanned hospitalisation in people with moderate to very severe idiopathic pulmonary fibrosis: the EME-TIPAC RCT. <i>Efficacy and Mechanism Evaluation</i> , 2021, 8, 1-110.	0.9	1
16	Selection and characterization of mutational resistance to aztreonam/avibactam in β -lactamase-producing Enterobacterales. <i>Journal of Antimicrobial Chemotherapy</i> , 2021, 77, 98-111.	1.3	11
17	INHALE: the impact of using FilmArray Pneumonia Panel molecular diagnostics for hospital-acquired and ventilator-associated pneumonia on antimicrobial stewardship and patient outcomes in UK Critical Careâ€™ study protocol for a multicentre randomised controlled trial. <i>Trials</i> , 2021, 22, 680.	0.7	17
18	Replacement of <i>Enterococcus faecalis</i> by <i>Enterococcus faecium</i> as the predominant enterococcus in UK bacteraemias. <i>JAC-Antimicrobial Resistance</i> , 2021, 3, dlab185.	0.9	7

#	ARTICLE	IF	CITATIONS
19	Therapeutic Potential of Injectable Nano-Mupirocin Liposomes for Infections Involving Multidrug-Resistant Bacteria. <i>Pharmaceutics</i> , 2021, 13, 2186.	2.0	5
20	Metallo- β -Lactamases: Structure, Function, Epidemiology, Treatment Options, and the Development Pipeline. <i>Antimicrobial Agents and Chemotherapy</i> , 2020, 64, .	1.4	127
21	Activity of ceftaroline versus ceftobiprole against staphylococci and pneumococci in the UK and Ireland: analysis of BSAC surveillance data. <i>Journal of Antimicrobial Chemotherapy</i> , 2020, 75, 3239-3243.	1.3	11
22	<i>In Vitro</i> Activity of Cefiderocol, a Siderophore Cephalosporin, against Multidrug-Resistant Gram-Negative Bacteria. <i>Antimicrobial Agents and Chemotherapy</i> , 2020, 64, .	1.4	65
23	Inherent colistin resistance in genogroups of the <i>Enterobacter cloacae</i> complex: epidemiological, genetic and biochemical analysis from the BSAC Resistance Surveillance Programme. <i>Journal of Antimicrobial Chemotherapy</i> , 2020, 75, 2452-2461.	1.3	20
24	Carbapenem-Resistant Enterobacterales, Carbapenem Resistant Organisms, Carbapenemase-Producing Enterobacterales, and Carbapenemase-Producing Organisms: Terminology Past its "Sell-By Date" in an Era of New Antibiotics and Regional Carbapenemase Epidemiology. <i>Clinical Infectious Diseases</i> , 2020, 71, 1776-1782.	2.9	47
25	Successful Treatment of Acute Prostatitis Caused by Multidrug-Resistant <i>Escherichia coli</i> With Tigecycline Monotherapy. <i>Open Forum Infectious Diseases</i> , 2020, 7, ofz551.	0.4	4
26	Effect of Co-trimoxazole (Trimethoprim-Sulfamethoxazole) vs Placebo on Death, Lung Transplant, or Hospital Admission in Patients With Moderate and Severe Idiopathic Pulmonary Fibrosis. <i>JAMA - Journal of the American Medical Association</i> , 2020, 324, 2282.	3.8	32
27	In-vitro activity of cefiderocol against multidrug-resistant Enterobacterales, <i>Pseudomonas aeruginosa</i> and <i>Acinetobacter baumannii</i> isolates from the UK. <i>Access Microbiology</i> , 2020, 2, .	0.2	3
28	Extended-spectrum β -lactamase-producing <i>Escherichia coli</i> in human-derived and foodchain-derived samples from England, Wales, and Scotland: an epidemiological surveillance and typing study. <i>Lancet Infectious Diseases</i> , The, 2019, 19, 1325-1335.	4.6	150
29	OXA-1 β -lactamase and non-susceptibility to penicillin/ β -lactamase inhibitor combinations among ESBL-producing <i>Escherichia coli</i> . <i>Journal of Antimicrobial Chemotherapy</i> , 2019, 74, 326-333.	1.3	91
30	Potential of imipenem by relebactam for <i>Pseudomonas aeruginosa</i> from bacteraemia and respiratory infections. <i>Journal of Antimicrobial Chemotherapy</i> , 2019, 74, 1940-1944.	1.3	18
31	Activity of nacubactam (RG6080/OP0595) combinations against MBL-producing Enterobacteriaceae. <i>Journal of Antimicrobial Chemotherapy</i> , 2019, 74, 953-960.	1.3	55
32	Compassionate Use of Cefiderocol as Adjunctive Treatment of Native Aortic Valve Endocarditis Due to Extremely Drug-resistant <i>Pseudomonas aeruginosa</i> . <i>Clinical Infectious Diseases</i> , 2019, 68, 1932-1934.	2.9	49
33	Treatment of infections caused by multidrug-resistant Gram-negative bacteria: report of the British Society for Antimicrobial Chemotherapy/Healthcare Infection Society/British Infection Association Joint Working Party. <i>Journal of Antimicrobial Chemotherapy</i> , 2018, 73, iii2-iii78.	1.3	246
34	<i>Pseudomonas aeruginosa</i> sequence type 357 with VEB extended-spectrum β -lactamases in the UK: relatedness and resistance. <i>International Journal of Antimicrobial Agents</i> , 2018, 52, 301-302.	1.1	5
35	Activity of ceftazidime/avibactam against problem Enterobacteriaceae and <i>Pseudomonas aeruginosa</i> in the UK, 2015-16. <i>Journal of Antimicrobial Chemotherapy</i> , 2018, 73, 648-657.	1.3	56
36	Potential of high-dose cefepime/tazobactam against multiresistant Gram-negative pathogens. <i>Journal of Antimicrobial Chemotherapy</i> , 2018, 73, 126-133.	1.3	26

#	ARTICLE	IF	CITATIONS
37	Selection of mutants with resistance or diminished susceptibility to ceftazidime/avibactam from ESBL- and AmpC-producing Enterobacteriaceae. <i>Journal of Antimicrobial Chemotherapy</i> , 2018, 73, 3336-3345.	1.3	26
38	The 2018 Garrod Lecture: Preparing for the Black Swans of resistance. <i>Journal of Antimicrobial Chemotherapy</i> , 2018, 73, 2907-2915.	1.3	23
39	The Efficacy and Mechanism Evaluation of Treating Idiopathic Pulmonary fibrosis with the Addition of Co-trimoxazole (EME-TIPAC): study protocol for a randomised controlled trial. <i>Trials</i> , 2018, 19, 89.	0.7	19
40	Activity of RX-04 Pyrrolocytosine Protein Synthesis Inhibitors against Multidrug-Resistant Gram-Negative Bacteria. <i>Antimicrobial Agents and Chemotherapy</i> , 2018, 62, .	1.4	3
41	Activity of ceftolozane/tazobactam against surveillance and "problem" Enterobacteriaceae, <i>Pseudomonas aeruginosa</i> and non-fermenters from the British Isles. <i>Journal of Antimicrobial Chemotherapy</i> , 2017, 72, 2278-2289.	1.3	109
42	In vitro activity of cefepime/zidebactam (WCK 5222) against Gram-negative bacteria. <i>Journal of Antimicrobial Chemotherapy</i> , 2017, 72, 1373-1385.	1.3	114
43	WCK 4234, a novel diazabicyclooctane potentiating carbapenems against Enterobacteriaceae, <i>Pseudomonas</i> and <i>Acinetobacter</i> with class A, C and D β -lactamases. <i>Journal of Antimicrobial Chemotherapy</i> , 2017, 72, 1688-1695.	1.3	24
44	Occurrence of carbapenemase-producing <i>Klebsiella pneumoniae</i> and <i>Escherichia coli</i> in the European survey of carbapenemase-producing Enterobacteriaceae (EuSCAPE): a prospective, multinational study. <i>Lancet Infectious Diseases</i> , The, 2017, 17, 153-163.	4.6	522
45	Etest \hat{A} versus broth microdilution for ceftaroline MIC determination with <i>Staphylococcus aureus</i> : results from PREMIUM, a European multicentre study. <i>Journal of Antimicrobial Chemotherapy</i> , 2017, 72, 431-436.	1.3	17
46	A Risk Assessment of Antibiotic Pan-Drug-Resistance in the UK: Bayesian Analysis of an Expert Elicitation Study. <i>Antibiotics</i> , 2017, 6, 9.	1.5	15
47	<i>In Vitro</i> Activity of Eravacycline against Carbapenem-Resistant Enterobacteriaceae and <i>Acinetobacter baumannii</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 3840-3844.	1.4	116
48	Interactions of OPO595, a Novel Triple-Action Diazabicyclooctane, with β -Lactams against OPO595-Resistant Enterobacteriaceae Mutants. <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 554-560.	1.4	34
49	KPC enzymes in the UK: an analysis of the first 160 cases outside the North-West region. <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, 1199-1206.	1.3	21
50	Susceptibility testing challenges with ceftaroline, MRSA and a 1 mg/L breakpoint. <i>Journal of Antimicrobial Chemotherapy</i> , 2015, 70, dkv265.	1.3	11
51	Longitudinal trends and cross-sectional analysis of English national hospital antibacterial use over 5 years (2008-13): working towards hospital prescribing quality measures. <i>Journal of Antimicrobial Chemotherapy</i> , 2015, 70, 279-285.	1.3	23
52	<i>In Vitro</i> Selection of Ceftazidime-Avibactam Resistance in Enterobacteriaceae with KPC-3 Carbapenemase. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 5324-5330.	1.4	142
53	Pathogens of skin and skin-structure infections in the UK and their susceptibility to antibiotics, including ceftaroline. <i>Journal of Antimicrobial Chemotherapy</i> , 2015, 70, 2844-2853.	1.3	21
54	OPO595, a new diazabicyclooctane: mode of action as a serine β -lactamase inhibitor, antibiotic and β -lactam "enhancer". <i>Journal of Antimicrobial Chemotherapy</i> , 2015, 70, 2779-2786.	1.3	127

#	ARTICLE	IF	CITATIONS
55	Genetic environment of metallo- β -lactamase genes in <i>Pseudomonas aeruginosa</i> isolates from the UK. <i>Journal of Antimicrobial Chemotherapy</i> , 2015, 70, dkv263.	1.3	11
56	Activity of OPO595 β -lactam combinations against Gram-negative bacteria with extended-spectrum, AmpC and carbapenem-hydrolysing β -lactamases. <i>Journal of Antimicrobial Chemotherapy</i> , 2015, 70, 3032-3041.	1.3	45
57	Cephalosporinases associated with outer membrane vesicles released by <i>Bacteroides</i> spp. protect gut pathogens and commensals against β -lactam antibiotics. <i>Journal of Antimicrobial Chemotherapy</i> , 2015, 70, 701-709.	1.3	93
58	Prevalence of ciprofloxacin-resistant Enterobacteriaceae in the intestinal flora of patients undergoing transrectal prostate biopsy in Norwich, UK. <i>BJU International</i> , 2015, 116, 131-134.	1.3	11
59	Dominance of international 'high-risk clones' among metallo- β -lactamase-producing <i>Pseudomonas aeruginosa</i> in the UK. <i>Journal of Antimicrobial Chemotherapy</i> , 2015, 70, 103-110.	1.3	81
60	Homogeneity of antimicrobial policy, yet heterogeneity of antimicrobial resistance: antimicrobial non-susceptibility among 108 717 clinical isolates from primary, secondary and tertiary care patients in London. <i>Journal of Antimicrobial Chemotherapy</i> , 2014, 69, 3409-3422.	1.3	35
61	In vitro activity of rifaximin against clinical isolates of <i>Escherichia coli</i> and other enteropathogenic bacteria isolated from travellers returning to the UK. <i>International Journal of Antimicrobial Agents</i> , 2014, 43, 431-437.	1.1	31
62	Distribution of β -lactamases in carbapenem-non-susceptible <i>Acinetobacter baumannii</i> in Riyadh, Saudi Arabia. <i>Journal of Global Antimicrobial Resistance</i> , 2014, 2, 17-21.	0.9	28
63	Aetiology and resistance in bacteraemias among adult and paediatric haematology and cancer patients. <i>Journal of Infection</i> , 2014, 68, 321-331.	1.7	223
64	NDM carbapenemases in the United Kingdom: an analysis of the first 250 cases. <i>Journal of Antimicrobial Chemotherapy</i> , 2014, 69, 1777-1784.	1.3	59
65	Decreased susceptibility to cephalosporins among gonococci? " Authors' reply. <i>Lancet Infectious Diseases</i> , The, 2014, 14, 186-187.	4.6	0
66	Comparative in vitro activity of sulfametrole/trimethoprim and sulfamethoxazole/trimethoprim and other agents against multiresistant Gram-negative bacteria. <i>Journal of Antimicrobial Chemotherapy</i> , 2014, 69, 1050-1056.	1.3	27
67	Of stewardship, motherhood and apple pie. <i>International Journal of Antimicrobial Agents</i> , 2014, 43, 319-322.	1.1	19
68	Methodological agreement on the in vitro activity of ceftaroline against cefotaxime-susceptible and -resistant pneumococci. <i>International Journal of Antimicrobial Agents</i> , 2014, 43, 131-134.	1.1	3
69	Clinical epidemiology of the global expansion of <i>Klebsiella pneumoniae</i> carbapenemases. <i>Lancet Infectious Diseases</i> , The, 2013, 13, 785-796.	4.6	1,328
70	Activity of biapenem (RPX2003) combined with the boronate β -lactamase inhibitor RPX7009 against carbapenem-resistant Enterobacteriaceae. <i>Journal of Antimicrobial Chemotherapy</i> , 2013, 68, 1825-1831.	1.3	86
71	Decreased susceptibility to cephalosporins among gonococci: data from the Gonococcal Resistance to Antimicrobials Surveillance Programme (GRASP) in England and Wales, 2007-2011. <i>Lancet Infectious Diseases</i> , The, 2013, 13, 762-768.	4.6	127
72	Activity of carbapenems with ME1071 (disodium 2,3-diethylmaleate) against Enterobacteriaceae and <i>Acinetobacter</i> spp. with carbapenemases, including NDM enzymes. <i>Journal of Antimicrobial Chemotherapy</i> , 2013, 68, 153-158.	1.3	48

#	ARTICLE	IF	CITATIONS
73	Activity of MK-7655 combined with imipenem against Enterobacteriaceae and <i>Pseudomonas aeruginosa</i> . <i>Journal of Antimicrobial Chemotherapy</i> , 2013, 68, 2286-90.	1.3	196
74	Declining cephalosporin and fluoroquinolone non-susceptibility among bloodstream Enterobacteriaceae from the UK: links to prescribing change?. <i>Journal of Antimicrobial Chemotherapy</i> , 2013, 68, 2667-2674.	1.3	83
75	Revolutionising Bacteriology to Improve Treatment Outcomes and Antibiotic Stewardship. <i>Infection and Chemotherapy</i> , 2013, 45, 1.	1.0	38
76	Characterization of \hat{A} -lactamase and porin mutants of Enterobacteriaceae selected with ceftaroline + avibactam (NXL104). <i>Journal of Antimicrobial Chemotherapy</i> , 2012, 67, 1354-1358.	1.3	55
77	Are susceptibility tests enough, or should laboratories still seek ESBLs and carbapenemases directly?. <i>Journal of Antimicrobial Chemotherapy</i> , 2012, 67, 1569-1577.	1.3	125
78	Diverse Sequence Types of <i>Klebsiella pneumoniae</i> Contribute to the Dissemination of <i>bla</i> _{NDM-1} in India, Sweden, and the United Kingdom. <i>Antimicrobial Agents and Chemotherapy</i> , 2012, 56, 2735-2738.	1.4	165
79	Fourteen years in resistance. <i>International Journal of Antimicrobial Agents</i> , 2012, 39, 283-294.	1.1	197
80	Current Epidemiology and Growing Resistance of Gram-Negative Pathogens. <i>Korean Journal of Internal Medicine</i> , 2012, 27, 128.	0.7	296
81	Phosphoethanolamine Modification of Lipid A in Colistin-Resistant Variants of <i>Acinetobacter baumannii</i> Mediated by the pmrAB Two-Component Regulatory System. <i>Antimicrobial Agents and Chemotherapy</i> , 2011, 55, 3370-3379.	1.4	354
82	What remains against carbapenem-resistant Enterobacteriaceae? Evaluation of chloramphenicol, ciprofloxacin, colistin, fosfomycin, minocycline, nitrofurantoin, temocillin and tigecycline. <i>International Journal of Antimicrobial Agents</i> , 2011, 37, 415-419.	1.1	292
83	Discovery research: the scientific challenge of finding new antibiotics. <i>Journal of Antimicrobial Chemotherapy</i> , 2011, 66, 1941-1944.	1.3	240
84	Dissemination of NDM-1 positive bacteria in the New Delhi environment and its implications for human health: an environmental point prevalence study. <i>Lancet Infectious Diseases</i> , The, 2011, 11, 355-362.	4.6	1,045
85	Strategies to overcome extended-spectrum $\hat{2}$ -lactamases (ESBLs) and AmpC $\hat{2}$ -lactamases in shigellae. <i>International Journal of Antimicrobial Agents</i> , 2011, 37, 405-409.	1.1	18
86	Multiresistant Gram-negative bacteria: the role of high-risk clones in the dissemination of antibiotic resistance. <i>FEMS Microbiology Reviews</i> , 2011, 35, 736-755.	3.9	728
87	Molecular epidemiology of fluoroquinolone-resistant ST131 <i>Escherichia coli</i> producing CTX-M extended-spectrum \hat{A} -lactamases in nursing homes in Belfast, UK. <i>Journal of Antimicrobial Chemotherapy</i> , 2011, 66, 297-303.	1.3	54
88	Variation in the genetic environments of blaCTX-M-15 in <i>Escherichia coli</i> from the faeces of travellers returning to the United Kingdom. <i>Journal of Antimicrobial Chemotherapy</i> , 2011, 66, 1005-1012.	1.3	76
89	Activities of NXL104 Combinations with Ceftazidime and Aztreonam against Carbapenemase-Producing <i>Enterobacteriaceae</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2011, 55, 390-394.	1.4	240
90	Prevalence of faecal carriage of Enterobacteriaceae with NDM-1 carbapenemase at military hospitals in Pakistan, and evaluation of two chromogenic media. <i>Journal of Antimicrobial Chemotherapy</i> , 2011, 66, 2288-2294.	1.3	163

#	ARTICLE	IF	CITATIONS
91	Decline of EMRSA-16 amongst methicillin-resistant <i>Staphylococcus aureus</i> causing bacteraemias in the UK between 2001 and 2007. <i>Journal of Antimicrobial Chemotherapy</i> , 2010, 65, 446-448.	1.3	86
92	Chequerboard titration of cephalosporin CXA-101 (FR264205) and tazobactam versus $\hat{\text{A}}$ -lactamase-producing Enterobacteriaceae. <i>Journal of Antimicrobial Chemotherapy</i> , 2010, 65, 1972-1974.	1.3	69
93	Cephalosporin resistance mechanisms in <i>Escherichia coli</i> isolated from raw chicken imported into the UK. <i>Journal of Antimicrobial Chemotherapy</i> , 2010, 65, 2534-2537.	1.3	78
94	Cephalosporin MIC creep among gonococci: time for a pharmacodynamic rethink?. <i>Journal of Antimicrobial Chemotherapy</i> , 2010, 65, 2141-2148.	1.3	154
95	Efflux Pumps, OprD Porin, AmpC $\hat{\text{I}}$ ² -Lactamase, and Multiresistance in <i>Pseudomonas aeruginosa</i> Isolates from Cystic Fibrosis Patients. <i>Antimicrobial Agents and Chemotherapy</i> , 2010, 54, 2219-2224.	1.4	130
96	AdeABC-mediated efflux and tigecycline MICs for epidemic clones of <i>Acinetobacter baumannii</i> . <i>Journal of Antimicrobial Chemotherapy</i> , 2010, 65, 1589-1593.	1.3	129
97	Emergence of AcrAB-mediated tigecycline resistance in a clinical isolate of <i>Enterobacter cloacae</i> during ciprofloxacin treatment. <i>International Journal of Antimicrobial Agents</i> , 2010, 35, 478-481.	1.1	36
98	Emergence of a new antibiotic resistance mechanism in India, Pakistan, and the UK: a molecular, biological, and epidemiological study. <i>Lancet Infectious Diseases</i> , The, 2010, 10, 597-602.	4.6	2,485
99	Nursing homes as a reservoir of extended-spectrum $\hat{\text{A}}$ -lactamase (ESBL)-producing ciprofloxacin-resistant <i>Escherichia coli</i> . <i>Journal of Antimicrobial Chemotherapy</i> , 2009, 64, 635-641.	1.3	182
100	Molecular mechanisms disrupting porin expression in ertapenem-resistant <i>Klebsiella</i> and <i>Enterobacter</i> spp. clinical isolates from the UK. <i>Journal of Antimicrobial Chemotherapy</i> , 2009, 63, 659-667.	1.3	390
101	Doripenem: antimicrobial profile and clinical potential. <i>Diagnostic Microbiology and Infectious Disease</i> , 2009, 63, 455-458.	0.8	28
102	Complete Nucleotide Sequences of Plasmids pEK204, pEK499, and pEK516, Encoding CTX-M Enzymes in Three Major <i>Escherichia coli</i> Lineages from the United Kingdom, All Belonging to the International O25:H4-ST131 Clone. <i>Antimicrobial Agents and Chemotherapy</i> , 2009, 53, 4472-4482.	1.4	256
103	Activity of cephalosporin CXA-101 (FR264205) against <i>Pseudomonas aeruginosa</i> and <i>Burkholderia cepacia</i> group strains and isolates. <i>International Journal of Antimicrobial Agents</i> , 2009, 34, 402-406.	1.1	69
104	Non-susceptibility trends among Enterobacteriaceae from bacteraemias in the UK and Ireland, 2001-06. <i>Journal of Antimicrobial Chemotherapy</i> , 2008, 62, ii41-ii54.	1.3	62
105	Arrival of <i>Klebsiella pneumoniae</i> producing KPC carbapenemase in the United Kingdom. <i>Journal of Antimicrobial Chemotherapy</i> , 2008, 62, 1261-1264.	1.3	126
106	UK epidemic <i>Escherichia coli</i> strains A-E, with CTX-M-15 $\hat{\text{A}}$ -lactamase, all belong to the international O25:H4-ST131 clone. <i>Journal of Antimicrobial Chemotherapy</i> , 2008, 62, 1241-1244.	1.3	151
107	In vitro activity of ceftaroline (PPI-0903M, T-91825) against bacteria with defined resistance mechanisms and phenotypes. <i>Journal of Antimicrobial Chemotherapy</i> , 2007, 60, 300-311.	1.3	132
108	CTX-M: changing the face of ESBLs in Europe. <i>Journal of Antimicrobial Chemotherapy</i> , 2006, 59, 165-174.	1.3	756

#	ARTICLE	IF	CITATIONS
109	The role of ISAbal in expression of OXA carbapenemase genes in <i>Acinetobacter baumannii</i> . FEMS Microbiology Letters, 2006, 258, 72-77.	0.7	669
110	In Vivo Development of Ertapenem Resistance in a Patient with Pneumonia Caused by <i>Klebsiella pneumoniae</i> with an Extended-Spectrum β -Lactamase. Clinical Infectious Diseases, 2006, 42, e95-e98.	2.9	126
111	Occurrence of Carbapenem-Resistant <i>Acinetobacter baumannii</i> Clones at Multiple Hospitals in London and Southeast England. Journal of Clinical Microbiology, 2006, 44, 3623-3627.	1.8	172
112	Ciprofloxacin resistance in <i>Neisseria gonorrhoeae</i> in England and Wales in 2002. Lancet, The, 2003, 361, 1867-1869.	6.3	92
113	Variable susceptibility to piperacillin/tazobactam amongst <i>Klebsiella</i> spp. with extended-spectrum beta-lactamases. Journal of Antimicrobial Chemotherapy, 2003, 51, 605-612.	1.3	19
114	Detection of CTX-M-15 extended-spectrum β -lactamase in the United Kingdom. Journal of Antimicrobial Chemotherapy, 2003, 52, 528-529.	1.3	39
115	Two widely disseminated strains of <i>Enterococcus faecalis</i> highly resistant to gentamicin and ciprofloxacin from bacteraemias in the UK and Ireland. Journal of Antimicrobial Chemotherapy, 2003, 52, 711-714.	1.3	22
116	Antibiotic resistance among clinical isolates of <i>Acinetobacter</i> in the UK, and in vitro evaluation of tigecycline (GAR-936). Journal of Antimicrobial Chemotherapy, 2002, 49, 479-487.	1.3	181
117	Multiple Mechanisms of Antimicrobial Resistance in <i>Pseudomonas aeruginosa</i> : Our Worst Nightmare?. Clinical Infectious Diseases, 2002, 34, 634-640.	2.9	1,165
118	Persistence of sulphonamide resistance in <i>Escherichia coli</i> in the UK despite national prescribing restriction. Lancet, The, 2001, 357, 1325-1328.	6.3	416
119	Interpretative reading: recognizing the unusual and inferring resistance mechanisms from resistance phenotypes. Journal of Antimicrobial Chemotherapy, 2001, 48, 87-102.	1.3	201
120	Carbapenem-Resistant <i>Klebsiella pneumoniae</i> in Singapore Producing IMP-1 β -Lactamase and Lacking an Outer Membrane Protein. Antimicrobial Agents and Chemotherapy, 2001, 45, 1939-1940.	1.4	45
121	Carbapenemases of <i>Chryseobacterium</i> (<i>Flavobacterium</i>) <i>meningosepticum</i> : Distribution of blaB and Characterization of a Novel Metallo- β -Lactamase Gene, blaB3 , in the Type Strain, NCTC 10016. Antimicrobial Agents and Chemotherapy, 2000, 44, 1448-1452.	1.4	40